Table 5.
Univariate and multivariate analyses of overall survival in patients with untreated brain metastasis. OR: odds ratio; 95% CI: 95% confidence interval; BM: brain metastasis; age: <65 versus ≥65; sex female versus male; ethnicity: Caucasian versus non-Caucasian; smoking status: smoker versus nonsmoker; primary tumor local treatment: surgery or radiation therapy versus no local treatment; Mutation status: EGFR mutant versus KRAS mutant versus KRAS and EGFR wild type tumors; WT: wild-type; number of metastases: one metastasis versus several metastases; *: significant p-value.
| Characteristics | Univariate Analyses | Multivariate Analyses | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
| OS of Patients with Untreated BM | ||||||
| Age | 1.018 | 0.968–1.071 | 0.484 | NA | NA | NA |
| Sex | 1.41 | 0.310–6.044 | 0.657 | NA | NA | NA |
| ECOG PS | 8.366 | 1.643–42.606 | 0.011 * | 8.768 | 0.493–155.954 | 0.139 |
| Smoking status | 0.951 | 0.203–4.449 | 0.949 | NA | NA | NA |
| Mutation status | 0.010 * | 0.698 | ||||
| EGFR mutant versus EGFR WT | 0.536 | 0.136–2.115 | 0.374 | 0.589 | 0.134–2.581 | 0.482 |
| KRAS mutant versus KRAS WT | 7.130 | 1.240–41.012 | 0.028 * | 0.356 | 0.015–8.224 | 0.519 |
| Synchronous or metachronous BM | 1.017 | 0.339–3.047 | 0.976 | NA | NA | NA |
| Number of metastases | 11.548 | 2236–59.640 | 0.003 * | 6.669 | 1.022–43.541 | 0.047 * |